Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    38
    ...
ATC Name B/G Ingredients Dosage Form Price
H02AB13 DEFAL B Deflazacort - 30mg 30mg Tablet 635,638 L.L
L04AX04 REVLIMID B Lenalidomide - 25mg 25mg Capsule 127,865,045 L.L
C09DB04 TWYNSTA B Telmisartan - 80mg, Amlodipine - 5mg Tablet 1,241,710 L.L
S02AA30 TYOTOCIN B Hexylresorcinol - 0.1%, Antipyrine - 5%, Benzocaine - 1.25%, Tyrothricin - 0.05% Drops solution 409,552 L.L
D03AX BEPANTHEN PLUS B Chlorhexidine HCl - 5mg/g, Dexpanthenol - 50mg/g Cream 319,835 L.L
H03AA01 EUTHYROX B Levothyroxine sodium - 25mcg 25mcg Tablet, scored 256,674 L.L
J05AB06 CYMEVENE B Ganciclovir (sodium) - 500mg 500mg Injectable solution 1,726,838 L.L
L01CD02 TAXOTERE B Docetaxel (trihydrated) - 20mg/ml 20mg/ml Injectable concentrated solution+diluent 6,574,078 L.L
A03FA03 MOTILIUM ORAL B Domperidone - 5mg/5ml 5mg/5ml Suspension 377,620 L.L
D03AX MEBO B ?-sitosterol - 0.25% 0.25% Ointment 760,615 L.L
G03CC06 GYNOFLOR B Estriol - 0.03mg, Lactobacillus acidophillus - 10 MIU Tablet 813,025 L.L
H03AA01 EUTHYROX B Levothyroxine sodium - 50mcg 50mcg Tablet, scored 391,058 L.L
J05AB11 VALTREX B Valaciclovir - 500mg 500mg Tablet, film coated 1,169,143 L.L
L01CD02 TAXOTERE B Docetaxel (trihydrated) - 20mg/ml 20mg/ml Injectable concentrated solution+diluent 6,574,078 L.L
M05BA04 BINOSTO B Alendronate sodium - 70mg 70mg Tablet, effervescent 1,709,368 L.L
S02CA02 VIOCORTENE B Clioquinol - 10mg/ml, Flumetasone pivalate - 0.2mg/ml Drops 568,253 L.L
G03CX01 LIVIAL B Tibolone - 2.5mg 2.5mg Tablet 1,135,547 L.L
H03AA01 ELTROXIN B Levothyroxine sodium - 100mcg 100mcg Tablet, scored 440,780 L.L
J05AB11 VALTREX B Valaciclovir - 500mg 500mg Tablet, film coated 4,481,715 L.L
M05BA06 BONVIVA B Ibandronic acid - 150mg 150mg Tablet, film coated 1,265,900 L.L
N03AG04 SABRIL B Vigabatrin - 500mg 500mg Tablet, film coated 2,988,706 L.L
A10BB12 AMARYL B Glimepiride - 4mg 4mg Tablet 392,402 L.L
G03DA03 PROLUTON DEPOT B Hydroxyprogesterone caproate - 250mg/ml 250mg/ml Injectable solution 270,112 L.L
H03AA01 EUTHYROX B Levothyroxine sodium - 100mcg 100mcg Tablet, scored 452,875 L.L
J01DH02 MERONEM B Meropenem (trihydrate) - 500mg 500mg Injectable powder for solution 10,398,061 L.L
G03DA04 UTROGESTAN B Progesterone micronised natural - 100mg 100mg Capsule 525,442 L.L
H03AA01 EUTHYROX B Levothyroxine sodium - 150mcg 150mcg Tablet, scored 615,480 L.L
R05CB06 MUCOSOLVAN B Ambroxol HCl - 30mg/5ml 30mg/5ml Syrup 380,307 L.L
A03FA07 GANATON B Itopride Hydrochloride - 50mg 50mg Tablet 1,119,421 L.L
G03DA04 UTROGESTAN B Progesterone micronised natural - 100mg 100mg Capsule 525,442 L.L
    ...
    38
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025